Active	Status	Sponsor type	Region	Phase	Filter
12 Active 1 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

12 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Burke, Deborah
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)	Recruiting	3	800	Europe, US, RoW	Remibrutinib, LOU064, Teriflunomide	Novartis Pharmaceuticals, Novartis Pharma AG	Relapsing Multiple Sclerosis	04/26	10/30
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)	Active, not recruiting	3	2196	Japan, US	Donanemab, LY3002813, Placebo	Eli Lilly and Company	Alzheimer Disease	11/27	11/27
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease	Completed	2/3	554	US	ATH-1017, Placebo	Athira Pharma	Alzheimer Disease, Dementia of Alzheimer Type	07/24	07/24
NCT06568042: Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy	Recruiting	2	450	Europe, Canada, Japan, US, RoW	LY3848575, Placebo	Eli Lilly and Company	Neuropathic Pain, Distal Sensory Polyneuropathy	06/26	09/26
NCT06219629: Parkinson's Disease Progression Study	Active, not recruiting	N/A	82	US		Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals	Parkinson Disease	02/26	02/26
Keegan, Andrew
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)	Recruiting	3	800	Europe, Canada, Japan, US, RoW	Remibrutinib, LOU064, Teriflunomide	Novartis Pharmaceuticals, Novartis Pharma AG	Relapsing Multiple Sclerosis	04/26	10/30
NCT05252949: OEA for Targeting Lipid Metabolism in GWI	Active, not recruiting	N/A	52	US	Oleoylethanolamide (OEA), Placebo	Roskamp Institute Inc., United States Department of Defense	Gulf War Illness	12/25	12/25
Abdullah, Laila
PACT, NCT03848312: Preventing Alzheimer's With Cognitive Training	Recruiting	3	7600	US	Cognitive Training, Computerized Cognitive Stimulation	University of South Florida, National Institute on Aging (NIA)	Age-related Cognitive Decline, Alzheimer's Disease and Related Dementias	01/26	01/26
NCT05252949: OEA for Targeting Lipid Metabolism in GWI	Active, not recruiting	N/A	52	US	Oleoylethanolamide (OEA), Placebo	Roskamp Institute Inc., United States Department of Defense	Gulf War Illness	12/25	12/25
NCT03082638: Identification of Gulf War Illness (GWI) Biomarkers	Active, not recruiting	N/A	76	US		Roskamp Institute Inc., United States Department of Defense	Gulf War Illness	12/24	12/24
NCT05243290: Nicotinamide Riboside Clinical Trial for GWI	Recruiting	N/A	52	US	Nicotinamide Riboside, Placebo	Roskamp Institute Inc., United States Department of Defense, Nova Southeastern University	Gulf War Illness	02/25	02/25
NCT05736146: Validating Gulf War Illness Blood Biomarkers	Recruiting	N/A	100	US		Roskamp Institute Inc., Boston University, Palo Alto Veterans Institute for Research, United States Department of Defense	Gulf War Syndrome, Gulf War Illness	06/25	03/26
Cinor, Sandra
No trials found
Alvarez, Yahdinah
No trials found
Davis, Lois
No trials found